鞘氨醇激酶(SphK1,SphK2)是鞘氨醇-1-磷酸酯(S1P)的主要调节剂,鞘氨醇-1-磷酸酯是一种参与多种生理和病理生理功能的多效脂质介体。SphK是新型抗癌和抗炎剂的靶标,这些抗癌剂和抗炎剂可促进细胞凋亡并调节自身免疫性疾病。本文中,我们描述了氨基噻唑类SphK抑制剂的设计,合成和评估。通过使用已知的SKI-II支架进行一系列修饰来定义结构-活性关系,已经发现了有效的抑制剂。我们确定了N-(4-甲基噻唑-2-基)-(2,4'-bithiazol)-2'-胺(24,ST-1803 ; IC 50 值:7.3μM(SphK1),6.5μM(SphK2))有望成为进一步体内研究和结构开发的有希望的候选者。
Synthesis and Biological Evaluation of N-aryl-4-aryl-1,3-Thiazole-2-Amine Derivatives as Direct 5-Lipoxygenase Inhibitors
作者:Jeehee Suh、Eul Kgun Yum、Hyae Gyeong Cheon、Young Sik Cho
DOI:10.1111/j.1747-0285.2012.01371.x
日期:2012.7
Biological evaluation of N‐aryl‐4‐aryl‐1,3‐thiazole‐2‐amine derivatives was examined for anti‐inflammatory activity in in vitro and in vivo assays. The thiazole compounds showed direct inhibition of 5‐lipoxygenase (LOX) that is a key enzyme of leukotrienes synthesis and involved in the inflammation‐related diseases, including asthma and rheumatoid arthritis. To optimize biological activity, we synthesized 1